Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

2seventy bio logo

About 2seventy bio Stock (NASDAQ:TSVT)

Advanced Chart

Key Stats

Today's Range
$5.00
$5.00
50-Day Range
$4.99
$5.00
52-Week Range
$2.29
$5.30
Volume
N/A
Average Volume
650,169 shs
Market Capitalization
$266.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TSVT Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More Headlines

TSVT Stock Analysis - Frequently Asked Questions

2seventy bio, Inc. (NASDAQ:TSVT) issued its earnings results on Wednesday, May, 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.11. The company earned $22.94 million during the quarter, compared to analysts' expectations of $13.96 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%.

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/07/2025
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSVT
CIK
1860782
Fax
N/A
Employees
440
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$217.57 million
Net Margins
-207.25%
Pretax Margin
-207.25%
Return on Equity
-53.65%
Return on Assets
-23.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.95
Quick Ratio
4.95

Sales & Book Value

Annual Sales
$48.37 million
Price / Sales
5.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.04 per share
Price / Book
0.99

Miscellaneous

Outstanding Shares
53,230,000
Free Float
47,874,000
Market Cap
$266.15 million
Optionable
Optionable
Beta
1.04
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:TSVT) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners